NATCO PHARMA LIMITED (INDIA).
“Sunitinib” is the Drug / Molecule content in “Sutinat”.
Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs).These include all receptors for platelet derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), which play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous inhibition of these targets therefore leads to both reduced tumor vascularization and cancer cell death and ultimately tumor shrinkage.
Sunitinib is indicated for the treatment of Gastrointestinal Stromal Tumor after disease progression on or intolerance to Imatinib Mesylate. It is also indicated for the treatment of Advance Renal Cell Carcinoma.
SIDE EFFECTS :
- The most common side effects associated with Sunitinib therapy are Fatigue, nausea, anorexia, Hypertension, a yellow skin discoloration, Hand-foot skin reaction, diarrhea, and Stomatitis.
- Serious side effects include Asthenia and Chemotherapy-induced acral erythema.
- Epigallocatechin-3-gallate, a major constituent of green tea, may reduce the Bioavailability of Sunitinib when they are taken together.
- Do not use more than prescribed dose.
- Patients who have received doses higher than those recommended should be carefully monitored.
- Do not take extra dose to make up for the missed dose.
- Sunitinib is a prescription drug and should be used under proper medical guidance and advice.
- It can cause serious liver problems, including death.
12.5 mg, 25 mg, 50 mg
1 X 28 Capsules in Plastic container
Store in a cool place, protect from light.